Hybio Pharmaceutical Co., Ltd. (SHE:300199)
22.67
-0.81 (-3.45%)
Aug 26, 2026, 3:04 PM CST
Hybio Pharmaceutical Revenue
Hybio Pharmaceutical had revenue of 389.14M CNY in the quarter ending June 30, 2026, with 62.50% growth. This brings the company's revenue in the last twelve months to 1.11B, up 25.03% year-over-year. In the year 2025, Hybio Pharmaceutical had annual revenue of 966.35M with 63.73% growth.
Revenue (ttm)
1.11B
Revenue Growth
+25.03%
P/S Ratio
18.12
Revenue / Employee
901.47K
Employees
1,226
Market Cap
20.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 966.35M | 376.15M | 63.73% |
| Dec 31, 2024 | 590.20M | 158.81M | 36.82% |
| Dec 31, 2023 | 431.38M | -272.94M | -38.75% |
| Jan 1, 2023 | 704.32M | -31.65M | -4.30% |
| Jan 1, 2022 | 735.97M | 14.25M | 1.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 15.96B |
| Livzon Pharmaceutical Group | 10.75B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Kangmei Pharmaceutical | 5.03B |
| Chengdu Kanghong Pharmaceutical Group | 4.31B |
| Betta Pharmaceuticals | 3.85B |
Hybio Pharmaceutical News
- 2 months ago - US Food and Drug Administration to review Hybio's generic GLP-1s - Reuters